Adjuvant Treatment After Resection of Stage IIB or IIC Cutaneous Melanoma
Patients with cutaneous amelanocytic melanoma following complete surgical resection of stage IIB or IIC disease are candidates for adjuvant systemic treatment according to current evidence-based guidelines.
This protocol applies specifically to patients with resected stage IIB or IIC cutaneous melanoma — a defined sub-population for whom adjuvant therapy should be offered following surgery.
Adjuvant Approach
Adjuvant systemic therapy is recommended in this post-resection setting. Specific agents and their administration schedules are detailed in the complete structured protocol.
Full regimen — including agent selection, scheduling, and duration — is available in the protocol →
References
DOI: 10.1200/JCO.23.01136
- Adjuvant pembrolizumab or nivolumab should be offered to patients with resected stage IIB or IIC melanoma.
- Pembrolizumab 200 mg iv once every 3 weeks for 52 weeks (EORTC 13259)
- Nivolumab 240 mg iv once every 2 weeks or once 480 mg iv once every 4 weeks for 52 weeks (CheckMate 23810 and US FDA label)
View source ↗